CIS

Silk Road Samarkand Projects Record-Breaking 2024

Retrieved on: 
Wednesday, January 31, 2024
MICE, Silk Road, Diplomacy, Travel, Convention, International Apparel Federation, Conference of the Parties, FIDE, Meeting, Politics, Commerce, Statistics, Private sector, SRS, Conservation, AIIB, Tourism, IAF, Council, Party, World Triathlon Cup, General assembly, CIS, Crowne Plaza, CMS, Culture, International Civil Aviation Organization, Holiday Inn, Conference

SAMARKAND, Uzbekistan, Jan. 31, 2024 /PRNewswire/ -- Management Company Silk Road Samarkand (SRS), which operates Central Asia's largest tourist complex, announced an impressive list of statistics from its banner year of 2023, and projects even greater success in 2024, making the transition from tourist magnet to world-class destination for Meetings, Incentives, Conferences, and Exhibitions (MICE).

Key Points: 
  • SAMARKAND, Uzbekistan, Jan. 31, 2024 /PRNewswire/ -- Management Company Silk Road Samarkand (SRS), which operates Central Asia's largest tourist complex, announced an impressive list of statistics from its banner year of 2023, and projects even greater success in 2024, making the transition from tourist magnet to world-class destination for Meetings, Incentives, Conferences, and Exhibitions (MICE).
  • During 2023, Silk Road Samarkand burnished its MICE credentials by hosting more than 24 major international, business and government events, which were attended by more than 30,000 people, including the heads of state of Uzbekistan, Italy, France, and Qatar.
  • That's why SRS was the first location in Samarkand to offer world-class MICE facilities and services.
  • In 2024, SRS will continue surprising tourists and participants in high class events with our hospitality, making this year a breakthrough for the tourism sector of our country and one of its main centers - Samarkand."

Silk Road Samarkand Projects Record-Breaking 2024

Retrieved on: 
Wednesday, January 31, 2024
MICE, Silk Road, Diplomacy, Travel, Convention, International Apparel Federation, Conference of the Parties, FIDE, Meeting, Politics, Commerce, Statistics, Private sector, SRS, Conservation, AIIB, Tourism, IAF, Council, Party, World Triathlon Cup, General assembly, CIS, Crowne Plaza, CMS, Culture, International Civil Aviation Organization, Holiday Inn, Conference

SAMARKAND, Uzbekistan, Jan. 31, 2024 /PRNewswire/ -- Management Company Silk Road Samarkand (SRS), which operates Central Asia's largest tourist complex, announced an impressive list of statistics from its banner year of 2023, and projects even greater success in 2024, making the transition from tourist magnet to world-class destination for Meetings, Incentives, Conferences, and Exhibitions (MICE).

Key Points: 
  • SAMARKAND, Uzbekistan, Jan. 31, 2024 /PRNewswire/ -- Management Company Silk Road Samarkand (SRS), which operates Central Asia's largest tourist complex, announced an impressive list of statistics from its banner year of 2023, and projects even greater success in 2024, making the transition from tourist magnet to world-class destination for Meetings, Incentives, Conferences, and Exhibitions (MICE).
  • During 2023, Silk Road Samarkand burnished its MICE credentials by hosting more than 24 major international, business and government events, which were attended by more than 30,000 people, including the heads of state of Uzbekistan, Italy, France, and Qatar.
  • That's why SRS was the first location in Samarkand to offer world-class MICE facilities and services.
  • In 2024, SRS will continue surprising tourists and participants in high class events with our hospitality, making this year a breakthrough for the tourism sector of our country and one of its main centers - Samarkand."

Bugcrowd Launches CrowdConnect Partner Program to Further Empower Global Ecosystem of Partners

Retrieved on: 
Tuesday, January 30, 2024
Noise, SAN, Mind, Software as a service, CIS, Ecosystem, Risk, Organization, Alchemy, Crowdsourcing, Growth, Cryptocurrency

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Bugcrowd, the only multi-solution crowdsourced cybersecurity platform, today launched the CrowdConnect™ Partner Program to empower global partners to leverage the crowd to defend against today's fast moving cyber adversaries. The CrowdConnect Partner Program accelerates the growth and maturity of Bugcrowd's rich ecosystem of partners by recruiting, enabling, and nurturing them to market, influence, integrate, sell and deliver cyber security solutions and offerings.

Key Points: 
  • SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Bugcrowd , the only multi-solution crowdsourced cybersecurity platform, today launched the CrowdConnect™ Partner Program to empower global partners to leverage the crowd to defend against today's fast moving cyber adversaries.
  • The CrowdConnect Partner Program accelerates the growth and maturity of Bugcrowd's rich ecosystem of partners by recruiting, enabling, and nurturing them to market, influence, integrate, sell and deliver cyber security solutions and offerings.
  • "We've designed CrowdConnect to be valuable for our partners, allowing them to differentiate their products through access to our Bugcrowd Platform.
  • The CrowdConnect Partner Program brings together partners spanning traditional and non-traditional channels – including Resale Partners, Managed Security Service Providers, Agent/Referral Partners, Consultants/Advisors, System Integrators, Technology Alliance and Referral Partners – ensuring they never face today's cybersecurity challenges alone.

Juniper Research Announces Winners of Telco Innovation 2024 Awards

Retrieved on: 
Wednesday, January 24, 2024
5G, Telecommunications, Software, Networks, Internet, Technology, IOT (Internet of Things), Mobile, Wireless, Senior, Gold, Trust, Tata Communications, CRMS, CIS, Partnership, VodafoneZiggo, Tata, CX, RCS, Digital, Fraud, SMS, Investment, SLA, TransUnion, Conversational commerce, Gold Award, RBM, Research, News, EVP

“We are delighted to be recognised as the Best Conversational Commerce Solution Provider at the Juniper Research Future Digital Awards 2024.

Key Points: 
  • “We are delighted to be recognised as the Best Conversational Commerce Solution Provider at the Juniper Research Future Digital Awards 2024.
  • “We’re honoured to be recognised by Juniper Research in the Best Customer Data Platform category for our work alongside VodafoneZiggo,” said Nicky Peterse, Lead Principal Customer Success Manager at BlueConic.
  • “We’re delighted to be recognised for three years running by Juniper Research for our solution in the security and fraud space.
  • These awards affirm our continuous commitment to maintaining leadership in innovation for monetisation and anti-fraud services, benefitting mobile operators and enterprises globally.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

Retrieved on: 
Monday, January 29, 2024
WLC, BLC, ASCO, RCT, CIS, Patient, Randomized controlled trial, Diagnosis, Society, Bladder cancer, RWS

The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.

Key Points: 
  • The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.
  • A total of 114 patients were in the full analysis set.
  • Nineteen patients were included in the real-world study (RWS).
  • The new drug application (NDA) for APL-1706 was accepted by the National Medical Products Administration (NMPA) in November 2023.

Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting

Retrieved on: 
Wednesday, January 24, 2024
Research, FDA, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Oncology, Ageing, RWE, Mortality, Carcinoma in situ, Patient, PST, Progression-free survival, Ferring Pharmaceuticals, ASCO, CIS, EQ-5D, BCG, University, Society, Urinary bladder, Recurrence, Food, Carcinoma, Safety, Work, Disease, Bladder cancer, Doctor of Health Science, Progress, Real, Clinical trial, NMIBC, Physician, Pharmaceutical industry

ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness, overall experiences, patterns of use, and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in a U.S. real-world setting.

Key Points: 
  • ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness, overall experiences, patterns of use, and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in a U.S. real-world setting.
  • “I am thrilled to be part of this ongoing research and among the first uro-oncologists to be treating patients with ADSTILADRIN in a clinical setting.
  • Final results from this prospective, multi-institutional study are expected at the end of 2026.
  • Trials in Progress Poster Session B: Urothelial Carcinoma
    Abstract #TPS705, Friday, Jan. 26 at 5:45 - 6:45 p.m. PST

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Puppet Extends Compliance Enforcement to Support Open-Source Puppet Users in Meeting CIS Benchmarks

Retrieved on: 
Tuesday, January 23, 2024
DNA, Organization, CIS, Automation, Perforce, DISA, Software, Product management, Medical device

MINNEAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Puppet by Perforce, the industry standard for secure infrastructure automation, today has extended Compliance Enforcement to help support open-source Puppet users in meeting security frameworks like Center for Internet Security (CIS) Benchmarks, DISA STIGs, and more.

Key Points: 
  • MINNEAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Puppet by Perforce, the industry standard for secure infrastructure automation, today has extended Compliance Enforcement to help support open-source Puppet users in meeting security frameworks like Center for Internet Security (CIS) Benchmarks, DISA STIGs, and more.
  • The new offering allows Open-Source Puppet users to leverage Puppet policy as code (PaC) for automated compliance aligned with popular security standards.
  • With the increasing need to maximize resources, the exhaustive task of managing and meeting compliance can now be streamlined.
  • For more information on Compliance Enforcement for Open-Source Puppet, visit the Puppet website .